Enlivex Therapeutics Ltd.

4.64+0.2610+5.96%Vol 34.86K1Y Perf -51.34%
Jun 24th, 2022 15:59 DELAYED
BID3.56 ASK4.99
Open4.45 Previous Close4.38
Pre-Market- After-Market-
 - -  - -%
Target Price
15.00 
Analyst Rating
Strong Buy 1.00
Potential %
223.28 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
9.61 
Earnings Rating
Market Cap62.47M 
Earnings Date
8th Aug 2022
Alpha0.01 Standard Deviation0.29
Beta1.10 

Today's Price Range

4.454.66

52W Range

3.6513.95

5 Year PE Ratio Range

-4.10-1.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
16.29%
1 Month
8.92%
3 Months
-14.55%
6 Months
-25.16%
1 Year
-51.34%
3 Years
-74.92%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ENLV4.640.26105.96
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.41-0.45-9.76
Q04 2021--0.26-
Q03 2021-0.21-0.199.52
Q02 2021-0.26-0.1734.62
Q01 2021-0.21-0.199.52
Q04 2020--0.43-
Q03 2020-0.18-0.1611.11
Q02 2020-0.24-0.234.17
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date8th Aug 2022
Estimated EPS Next Report-0.45
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume34.86K
Shares Outstanding13.46K
Shares Float17.22M
Trades Count322
Dollar Volume158.86K
Avg. Volume48.98K
Avg. Weekly Volume22.48K
Avg. Monthly Volume42.87K
Avg. Quarterly Volume81.60K

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) stock closed at 4.64 per share at the end of the most recent trading day (a 5.96% change compared to the prior day closing price) with a volume of 34.86K shares and market capitalization of 62.47M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Enlivex Therapeutics Ltd. CEO is Oren Hershkovitz.

The one-year performance of Enlivex Therapeutics Ltd. stock is -51.34%, while year-to-date (YTD) performance is -25.76%. ENLV stock has a five-year performance of %. Its 52-week range is between 3.65 and 13.95, which gives ENLV stock a 52-week price range ratio of 9.61%

Enlivex Therapeutics Ltd. currently has a PE ratio of -3.70, a price-to-book (PB) ratio of 0.94, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -21.12%, a ROC of -23.05% and a ROE of -23.17%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Enlivex Therapeutics Ltd., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. Enlivex Therapeutics Ltd.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Enlivex Therapeutics Ltd. is Strong Buy (1), with a target price of $15, which is +223.28% compared to the current price. The earnings rating for Enlivex Therapeutics Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Enlivex Therapeutics Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Enlivex Therapeutics Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.13, ATR14 : 0.34, CCI20 : 23.10, Chaikin Money Flow : 0.01, MACD : -0.13, Money Flow Index : 30.19, ROC : -1.07, RSI : 53.83, STOCH (14,3) : 57.14, STOCH RSI : 1.00, UO : 55.12, Williams %R : -42.86), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Enlivex Therapeutics Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

CEO: Oren Hershkovitz

Telephone: +972 26208072

Address: 14 Einstein Street, Nes Ziona 7403618, , IL

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

63%37%

Bearish Bullish

52%48%

News

Stocktwits